Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer Review uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Colorectal Neoplasms

abstract

  • In clinical trials, PS2 patients derive similar benefit from superior treatment as patients with PS of 0 to 1 but with an increased risk of toxicities and 12% 60-day mortality. Although current treatment provides benefit, new approaches are required to approach 1-year median survival for PS2 patients.

publication date

  • April 20, 2009

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC2669760

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.20.2879

PubMed ID

  • 19255311

Additional Document Info

start page

  • 1948

end page

  • 55

volume

  • 27

number

  • 12